Discounted Cash Flow (DCF) Analysis Levered
Champions Oncology, Inc. (CSBR)
$4.24
-0.06 (-1.40%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 20.24 | 27.07 | 32.12 | 41.04 | 49.11 | 61.36 | 76.68 | 95.81 | 119.73 | 149.60 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -1.23 | 1.86 | 2.91 | -1.68 | 6.50 | 2.33 | 2.91 | 3.64 | 4.55 | 5.68 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -1.23 | -0.83 | -2.22 | -3.28 | -2.38 | -3.55 | -4.43 | -5.54 | -6.92 | -8.65 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -2.45 | 1.03 | 0.69 | -4.96 | 4.11 | -1.22 | -1.52 | -1.90 | -2.37 | -2.97 |
Weighted Average Cost Of Capital
| Share price | $ 4.24 |
|---|---|
| Beta | 0.983 |
| Diluted Shares Outstanding | 14.16 |
| Cost of Debt | |
| Tax Rate | 6.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.259 |
| Total Debt | 9.47 |
| Total Equity | 60.04 |
| Total Capital | 69.50 |
| Debt Weighting | 13.62 |
| Equity Weighting | 86.38 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 20.24 | 27.07 | 32.12 | 41.04 | 49.11 | 61.36 | 76.68 | 95.81 | 119.73 | 149.60 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.23 | 1.86 | 2.91 | -1.68 | 6.50 | 2.33 | 2.91 | 3.64 | 4.55 | 5.68 |
| Capital Expenditure | -1.23 | -0.83 | -2.22 | -3.28 | -2.38 | -3.55 | -4.43 | -5.54 | -6.92 | -8.65 |
| Free Cash Flow | -2.45 | 1.03 | 0.69 | -4.96 | 4.11 | -1.22 | -1.52 | -1.90 | -2.37 | -2.97 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -3.03 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | 0.46 |
| Equity Value | - |
| Shares Outstanding | 14.16 |
| Equity Value Per Share | - |